Sinovac Selected by Beijing CDC to Supply Seasonal Influenza Vaccine Anflu(R) to Beijing Citizens

BEIJING, October 13, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention (Beijing CDC) as one of the four manufacturers to supply seasonal influenza vaccine to the citizens of Beijing for the fourth time.

Dr. Weidong Yin, Chairman, President and CEO of Sinovac, stated, "We are pleased to be chosen as one of the suppliers by the Beijing CDC for the seasonal flu vaccine campaign for the year of 2011. After the comprehensive evaluation of several different factors including product quality, service and price, Sinovac was selected for the fourth time, which further validates the high quality of our flu vaccine and our commitment to service as recognized by CDC customers. We look forward to working closely with the Beijing CDC to deliver our Anflu vaccine to the citizens under the vaccination campaign."

Starting in 2007, to prevent and control the seasonal flu, the Beijing CDC began purchasing the seasonal flu vaccines to immunize the elderly over 60 and the elementary and secondary school students in Beijing.

In 2011, the Beijing CDC plans to order a total of two million doses for this vaccination campaign. The total quantity to be supplied will depend on the actual demand in Beijing. In 2010, total about 269,000 doses of Anflu were inoculated to the target population for the vaccination campaign in Beijing. According to the Beijing Health Bureau's data as of November 30, 2010, approximately 1.6 million Beijing citizens were inoculated with the seasonal flu vaccines, inclusive of the target population covered by the free vaccination campaign.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), Japanese Encephalitis, animal and human rabies, HIB and epidemic meningitis, chickenpox, mumps and rubella. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines, and has launched its internally developed inactivated rabies vaccine in China.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.